The DOCK2 Knockout SK-OV-3 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-OV-3 human ovarian adenocarcinoma cell line. This product provides a heterogeneous pool of cells with targeted disruption of the DOCK2 gene, enabling loss-of-function studies without clonal selection. The polyclonal format preserves population-level diversity while abrogating DOCK2 protein expression, offering a robust model for investigating DOCK2-dependent processes in an epithelial ovarian cancer background.
SK-OV-3 cells were originally established from the ascites of a patient with ovarian serous cystadenocarcinoma and exhibit an adherent, epithelial morphology. As a widely used model for high-grade serous ovarian cancer, these cells retain key oncogenic signaling pathways and invasive properties characteristic of metastatic disease. Their tumorigenic nature makes them a suitable host to assess the impact of DOCK2 loss on malignant phenotypes, particularly motility and cytoskeletal reorganization.
DOCK2 encodes a guanine nucleotide exchange factor (GEF) that specifically activates Rac GTPases, thereby regulating actin cytoskeleton dynamics. In response to upstream signals from chemokine receptors (e.g., CXCR4), integrins, and growth factor receptors, DOCK2 catalyzes GDP-GTP exchange on Rac1. Active Rac1 then engages downstream effectors such as PAK kinases, the WAVE complex, and the Arp2/3 complex, leading to actin polymerization. The canonical chemokine ?? GPCR ?? DOCK2 ?? Rac1 ?? PAK ?? LIMK ?? cofilin axis orchestrates cell polarization and migration. DOCK2 also interacts with ELMO proteins, NCK, and WASP to coordinate immune synapse formation, though in epithelial cells its role converges on cytoskeletal remodeling.
Although DOCK2 is predominantly studied in lymphocytes, its expression in SK-OV-3 cells suggests a non-hematopoietic function in tumor biology. DOCK2-mediated Rac activation likely drives ovarian cancer cell migration and invasion, processes critical for metastasis. Disruption of DOCK2 is expected to impair Rac1-dependent actin dynamics, thereby attenuating chemotactic responses and matrix invasion. This knockout model thus enables dissection of DOCK2 contributions to tumor cell motility and potential cross-talk with immune evasion mechanisms, given DOCK2’s known role in immune cell function.
Researchers can employ these polyclonal knockout cells to evaluate DOCK2-dependent phenotypes using a suite of functional assays. Western blotting for DOCK2 and downstream phospho-PAK confirms knockout efficacy and signaling disruption. Transwell migration and invasion assays directly quantify motility deficits, while Rac1 GTPase activation assays measure nucleotide exchange activity. Immunofluorescence for F-actin reveals cytoskeletal architecture changes, and flow cytometry for integrin expression probes adhesion receptor modulation. These applications facilitate investigation of chemokine-driven metastasis and tumor-immune interactions. For further technical details, please contact Ascent Research.
